Table 1.
Baseline characteristics and demographics of study participants
| Variable | Coronavirus Disease 2019 AKI | Coronavirus Disease 2019 No AKI Control | ||||||
|---|---|---|---|---|---|---|---|---|
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | |
| Age, yr | 32 | 62 | 46 | 49 | 81 | 60 | 62 | 38 |
| Sex | M | M | F | M | M | M | F | M |
| Race | AA | AA | AA | AA | White | White | AA | White |
| BMI, kg/m2 | 32.1 | 40.5 | 26.6 | 28.4 | 35.2 | 29.1 | 34.2 | 58.0 |
| sCr baseline, mg/dl | 1.8 | 1.3 | 0.8 | 1.2 | 0.7 | 0.8 | 0.7 | 0.8 |
| sCr at collection, mg/dl | 3.5 | 2.1 | 1.5 | 2.6 | 2.3 | 0.8 | 0.8 | 0.9 |
| Comorbidities | ||||||||
| Diabetes | X | X | X | X | X | |||
| HTN | X | X | X | X | ||||
| Hyperlipidemia | X | X | X | X | X | |||
| CAD | X | X | X | |||||
| COPD/asthma | X | |||||||
| Baseline GFR <60 | X | X | X | |||||
| Foley catheter | X | |||||||
AKI was defined using the Kidney Disease Improving Global Outcomes criteria of rise in sCr of >0.3 mg/dl or 1.5× baseline. Clinical data from patients with noncoronavirus disease 2019 AKI (patients 9–12) were not obtained as samples were collected anonymously. M, male; F, female; AA, Black; BMI, body mass index, sCR, serum creatinine; X, patients with comorbidity; HTN, hypertension; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease.